carry

Alvara Protocol Raises $2.4M in Lightning Public Round

  Alvara Protocol is looking set to play a substantial role in redefining how the world invests. Their groundbreaking infrastructure, that is set to be an industry first, leverages the ERC-7621 (BTS or Basket Token Standard) to facilitate the creation of fully decentralized tokenized cryptocurrency investment funds. Now, anyone can now become a fund manager with ease. The responsibility for managing funds is something that has long been gatekept. Reserved for institutions or those already financially established. This is no longer the case. Alvara are poised to empower the next

Ex-Singapore Parliamentarian’s Swiss Company Launches Swiss Franc and Euro Stablecoins

Singapore investor and former parliamentarian Calvin Cheng's newly rebranded Swiss company, Anchored Coins, was granted membership in the Swiss VQF in early 2023. VQF is the largest and oldest cross-industry self-regulatory organisation in Switzerland and is officially recognised by FINMA, the country's financial services watchdog. Anchored Coins is launching a Swiss Franc-backed stablecoin (ACHF) and a Euro-backed stablecoin (AEUR), and will be issued on the Ethereum and BNB Chain blockchains. DCS Card Centre in Singapore is planning to issue credit cards collateralised by AEUR and ACHF. ZURICH, SWITZERLAND, Aug 16,

Cryptocurrencies in comparison: Bitcoin vs. Polygon

Bitcoin, the best-known and first decentralized cryptocurrency, paved the way for a variety of other digital currencies based on blockchain technology. One such currency that is attracting more and more attention lately is Polygon. However, Bitcoin is still the largest and most important cryptocurrency for a reason. So, can Polygon take on the crypto giant? The most important facts about Bitcoin Bitcoin is a decentralized digital currency invented in 2009 by an unknown person named Satoshi Nakamoto. It enables peer-to-peer transactions without a central intermediary. Blockchain technology serves as a public ledger that tracks transactions. Bitcoin

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating